Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised

4.7 (645) · € 19.00 · En Stock

Systemic Treatment Sequencing and Prediction of First-line Therapy

Induction docetaxel, cisplatin, and cetuximab followed by

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil

Cetuximab, docetaxel, and cisplatin as first-line treatment in

Cetuximab, docetaxel, and cisplatin as first-line treatment in

Durvalumab with or without tremelimumab versus the EXTREME regimen

Systemic Treatment Sequencing and Prediction of First-line Therapy

Frontiers TTCC-2019-02: real-world evidence of first-line

Frontiers The Evolving Role of Taxanes in Combination With

PDF] Cisplatin and fluorouracil with or without panitumumab in

Cetuximab, docetaxel, and cisplatin as first-line treatment in

The dogma of cetuximab in advanced squamous cell carcinoma of the